James Turner
Bio
Articles
LCL Resources (ASX: $LCL) Confirms Gold-Copper Porphyry Discovery at Dada, PNG
LCL Resources Ltd (ASX: LCL) Exploration Update on PNG Liamu Project LCL Resources Ltd (ASX: LCL) has announced a significant milestone at its 100%-owned Liamu Gold-Copper Project in Papua New Guinea (PNG), confirming the discovery of a substantial gold-copper porphyry system at the Dada prospect. The company’s recent trenching and pitting program has revealed encouraging […]
November 11, 2024
Siren Gold Limited (ASX: $SNG) Strikes High-Grade Gold at Victory United Reef, Signaling Promising Future
Siren Gold Limited (ASX: $SNG) recently unveiled significant high-grade gold assays from its Victory United Reef located at the Lyell tenement within the Reefton Project, drawing substantial attention in the mining community. These promising results may mark a new era of prosperity for the company in the gold mining sector. Introduction to the Discovery Recent […]
October 15, 2024
Cycliq Group Limited (ASX: $CYQ) – Q1 FY25 Quarterly Cash Flow Summary
Cycliq Group Limited (ASX: $CYQ) has released its quarterly cash flow report for the period ending 30 September 2024, detailing a mix of challenges and strategic movements within its financial structure. Key Financial Activities The report highlights the total receipts from customers standing at $1,083k for the quarter, supporting the primary revenue generation activities. However, […]
October 15, 2024
Nanoveu Limited (ASX: $NVU) Faces Suspension from Quotation
Nanoveu Limited (ASX: $NVU), a listed entity on the Australian Securities Exchange, has entered into a suspension from quotation effective immediately, according to a market announcement by ASX Compliance on 15 October 2024. The decision comes under Listing Rule 17.3 and follows closely on the heels of a trading halt requested by the company just […]
October 15, 2024
Riversgold Limited (ASX: $RGL) Embarks on High-Grade Multi-Metal Exploration at Saint John Project
Riversgold Limited (ASX: $RGL), a burgeoning force in the mining sector, has recently embarked on a significant exploration venture at their new Saint John Project in New Brunswick, Canada. This site visit, led by senior management, marks a strategic exploration of high-grade antimony, copper, gold, and silver deposits. Located conveniently near infrastructure and the US […]
October 15, 2024
ADX Energy Ltd (ASX: $ADX) Provides Comprehensive Update on LICHT-1 Well Drilling Operations
ADX Energy Ltd (ASX: $ADX) has issued a detailed update on its ongoing operations at the Lichtenberg-1 (LICHT-1) gas exploration well, located in its ADX-AT-I license in Upper Austria. The drilling campaign, which began on September 26, 2024, is leveraging the technical capabilities of the RED Drilling & Services GmbH (RED) E-202 rig, the same […]
October 15, 2024
ASX Travel Shares: A Look at Their Post-Pandemic Recovery
How Have ASX Travel Stocks Performed Since the COVID-19 Pandemic? The COVID-19 pandemic had a massive impact on the ASX travel sector, with share prices plummeting as international and domestic travel came to a halt. It was an unprecedented event, reminding investors of the need to diversify their portfolios. Now, with the pandemic declared over […]
October 10, 2024
Top 5 ASX Retail Stocks Beating Inflation in 2024
Despite the challenges of high inflation and rising interest rates, some Australian retail stocks have shown resilience in 2024. By adapting their strategies, focusing on customer engagement, and leveraging technology, these companies have managed to thrive. In this article, we’ll explore five top-performing ASX retail stocks, looking at their year-to-date performance, strategic initiatives, and potential […]
October 10, 2024
ASX Small-Cap Stock Lands Major Rio Tinto (ASX: $RIO) Partnership for Biofuels
What Is the Rio Tinto and Midway Partnership About? One of Australia’s largest small-cap companies, Midway Ltd (ASX: MWY), has seen its stock rise as news broke of a significant partnership with mining giant Rio Tinto (ASX: RIO). Early Wednesday morning, Midway’s shares climbed by 1% to $1.16, sparking excitement among investors. This partnership could […]
October 10, 2024
Most Common Retirement Mistakes and How To Avoid Them
Retirement planning is one of the most critical financial journeys we embark on in our lifetime. While it might seem distant when you’re younger, it’s a phase that sneaks up quickly. For many people, especially Generation X (born between 1966 and 1980), planning for retirement can be particularly challenging. They often find themselves caught between […]
September 18, 2024
Healthcare Stocks to Buy Hand Over Fist in September
As the healthcare sector continues to thrive amid global health challenges and an ageing population, savvy investors are increasingly eyeing opportunities in this resilient market. September presents a particularly compelling window to invest in some standout healthcare stocks that are not only performing well but also have strong potential for future growth. Among these, OncoSil […]
September 5, 2024
Top 5 ASX Stocks to Watch: Expert Picks
In the ever-evolving world of stock markets, staying informed about the most promising investments is crucial. For FY25, several standout companies on the ASX have caught the attention of top brokers. Here are the top five stocks to watch, handpicked by experts, offering a blend of growth potential and robust financial performance. 1. Pro Medicus […]
August 29, 2024
What Should I Look For When Buying Dividend Shares?
For many investors, dividends form the backbone of a diversified portfolio, while for others, they may not be a priority. Whether or not you focus on dividends depends largely on your investment approach and temperament. However, if you’re considering dividend shares, understanding the key factors to evaluate is crucial to making informed decisions. The Basics […]
August 29, 2024
Is Now The Time to Invest in These Mining Stocks?
Investing in mining stocks is a strategy that many consider when looking for stable returns, especially in a volatile market. Given the current volatility in commodity prices, the mining industry’s overall market downturn may present a favourable opportunity to determine whether these stocks should be included in your portfolio. Additionally, you have the option to […]
August 29, 2024
Why Could Investing in ASX Healthcare Shares Be Your Best Investment?
What are ASX Healthcare Shares? ASX healthcare shares are stocks of companies listed on the Australian Securities Exchange (ASX) that operate within the healthcare sector. These companies may be involved in pharmaceuticals, biotechnology, medical devices, healthcare services, and more. They are pivotal in enhancing health outcomes through innovation and the development of new treatments and […]
July 23, 2024
Sirtex Heavyweights Quietly Join OncoSil Medical (ASX: OSL): Who’s Blinking?
In a move that could signal significant growth potential, two prominent figures from Sirtex Medical have recently thrown their weight behind OncoSil Medical (ASX: OSL). Peter Hall and Gilman Wong, both major players in Sirtex’s rise to a billion-dollar company, have made substantial investments in OncoSil Medical. This development, along with Hall’s new role on […]
July 23, 2024
The Best Medical Stock That Not Nearly Enough People Are Talking About, and Why You Should Be
When it comes to investing in medical stocks, many investors focus on the big names. However, there’s one stock that’s flying under the radar but has immense potential: OncoSil Medical (ASX: OSL). Recently, the company has garnered attention due to significant investments and involvement from prominent figures like Peter Hall and Gilman Wong, both of […]
July 22, 2024
The Crucial Role of Clinical Trials in OncoSil Medical’s (ASX: OSL) Journey to Innovation
For investors in the healthcare sector, understanding the significance of clinical trials is vital. OncoSil Medical Ltd. (ASX: OSL) is making significant strides in the fight against pancreatic cancer through its innovative OncoSilâ„¢ device. Clinical trials like PANCOSIL and TRIPP-FFX not only validate OncoSil’s technological advancements but also underscore its commitment to revolutionising cancer treatment. […]
July 16, 2024
Best ASX Medical Device Stocks to Buy in 2024
With the global medical device market size surpassing $500 billion and poised to soar to nearly $800 billion by 2030, it’s no wonder that investors are flocking to this booming sector. The Australian Securities Exchange (ASX) is home to some of the most innovative and growth-oriented companies in the medical device industry. If you’re looking […]
July 15, 2024
2 Top ASX Healthcare Stocks You Need In Your Portfolio This July 2024
Healthcare businesses tend to hold up through various economic cycles. The healthcare sector is a beacon of resilience, consistently weathering economic storms while continuing to provide essential products and services. As we navigate the cyclical nature of the stock market, investing in healthcare stocks remains a wise strategy for long-term growth. This July, two ASX-listed […]
July 15, 2024
Why These 4 ASX Biotech Stocks Could Be a Better Bet Than AI in 2024
As the new financial year begins, investors are reconsidering their strategies and evaluating which ASX stocks to buy amid the current market conditions. In FY 2024, artificial intelligence (AI) stole the spotlight, but its reign may not be as enduring as some once thought. Several issues are raising concerns about AI’s continued dominance: In this […]
July 15, 2024
What’s the outlook for ASX healthcare shares in FY25?
ASX Healthcare: Set for a Sizzling FY25! The ASX healthcare sector has been a rollercoaster of innovation, challenges, and growth. Despite a modest underperformance compared to the broader S&P/ASX 200 Index (ASX: XJO) last year, FY25 is shaping up to be a thrilling ride for healthcare shares. With a mix of groundbreaking technology, demographic shifts, […]
July 13, 2024
Top 5 Biotech Stocks of July 2024
The biotech sector in Australia is known for its volatility and high stakes in clinical trials. Meanwhile, the performance of stocks is driven by company-specific developments, such as trial data as opposed to broad economic factors. This means that the sector is generally regarded as non-cyclical and equally provides benefits that are associated with diversification. […]
July 12, 2024
Incredible Growth Stock You’ll Regret Not Buying on the Dip
In the volatile world of biotech stocks, significant price fluctuations are not uncommon. However, these fluctuations often present excellent buying opportunities for savvy investors. One such opportunity is OncoSil Medical Limited (ASX: OSL), a pioneering company in the fight against pancreatic cancer. Despite its recent downturn, OncoSil Medical offers compelling signs that suggest it is […]
July 12, 2024
OncoSil Medical (ASX : OSL) Announces Strategic Issue of Options to Drive Growth and Innovation
OncoSil Medical Limited (ASX: OSL) has recently unveiled a strategic move aimed at bolstering its financial flexibility and supporting its growth initiatives. On June 21, 2024, the company announced the proposed issuance of 75 million options, which will expire on June 30, 2025, with an exercise price of AUD 0.009 per option. This significant step […]
July 3, 2024
OncoSil Medical (ASX: OSL): Leading the Charge Against Pancreatic Cancer with Single-Use Targeted Beta Radiation Device
Pancreatic cancer remains one of the most formidable challenges in oncology, often dubbed a “silent killer” due to its subtle, easily misinterpreted symptoms. With a survival rate hovering in the single digits, early diagnosis and effective treatment are critical yet elusive goals. OncoSil Medical Ltd. (ASX), an innovative global medical device company, is stepping up […]
July 3, 2024
OncoSil Medical’s Momentum: New Milestones in Cancer Treatment and Strategic Market Expansion
Key Highlights OncoSil Medical, a pioneering Australian-based company specialising in pancreatic cancer treatment devices, continues to forge ahead in its mission to transform cancer care. The company has recently reached several pivotal milestones that underscore its growth trajectory and dedication to improving patient outcomes. Investors and traders should note the strategic advancements OncoSil Medical is […]
July 2, 2024
OncoSil Medical (ASX: OSL) Pushes Clinical Boundaries
OncoSil Medical Ltd. (ASX:OSL), a company dedicated to advancing cancer treatment through innovative localised therapies, is pushing forward with two pivotal clinical trials: TRIPP-FFX and PANCOSIL. These trials are critical to their strategy of expanding the applications and accessibility of their flagship device, OncoSilâ„¢. This device delivers localised radiation therapy directly to pancreatic tumours, potentially […]
June 29, 2024
OncoSil Medical (ASX: OSL) Global Expansion Gaining Momentum
In 2023, OncoSil focused on regulatory and ethics approvals, and site training in over eighteen (18) hospitals that are fully trained to treat patients using the OncoSil device. Commercial progress was seen in Spain with a total of 7 hospitals already performing commercial treatments, and a further 3 hospitals were trained to begin treating patients. […]
June 29, 2024
Oncosil Medical (ASX: OSL) – Investors Presentation
OncoSil Medical (ASX: OSL) CEO & Managing Director Nigel Lange presented the company recently to investors, providing more detail into the nature of the treatment, clinical trials, and some indications as to how the recent capital raise is being used. In this article, we provide a summary of the main points from the Webinar, charting […]
June 27, 2024
OncoSil Medical (ASX:OSL) Device: Targeted Solutions for Pancreatic Cancer Treatment
OncoSil Medical Ltd. (ASX:OSL) is making remarkable strides in cancer treatment with its cutting-edge product, the OncoSilâ„¢ device. Specialising in localised radiation therapy for pancreatic cancer, OncoSil Medical is dedicated to enhancing treatment options for patients facing this formidable disease. As the company pursues global expansion, it is strategically advancing its technology through key clinical […]
June 26, 2024
5th Patient Treated with OncoSil Medical’s (ASX: OSL) OncoSil Device in PANCOSIL Trial
Main Highlights What happened? Pancreatic cancer treatment device company OncoSil Medical (ASX: OSL) has treated its fifth patient under the PANCOSIL clinical trial. The Netherlands-based investigator started clinical trials that are conducted at the AMC Medical Centre in Amsterdam in collaboration with Oncosil Medical. Why it Matters? The company said the next step in the […]
June 25, 2024
OncoSil Medical Ltd (ASX: OSL) Reaches Major Milestone with 200th Patient Treated Using OncoSil Device
Recent Developments in Pancreatic Cancer Treatment The 200th patient treatment using the OncoSil device has been announced by OncoSil Medical Ltd. This marks a noteworthy achievement for the company’s brachytherapy technology, which is used to treat locally advanced, unresectable pancreatic cancer. The procedure, which was performed at the Royal Adelaide Hospital, demonstrates how the gadget […]
June 24, 2024
OncoSil Medical’s (ASX: OSL) Journey Towards US Market Approval
Understanding OncoSil’s FDA Approval Process OncoSil Medical Ltd. (ASX:OSL) is striving to enter the US market with its innovative cancer treatment, OncoSilâ„¢. This device delivers beta radiation directly to pancreatic tumours, aiming to shrink them and improve patient outcomes. Securing FDA approval is crucial for OncoSil to market its product in the competitive US healthcare […]
June 24, 2024
OncoSil Medical’s Future in Focus: Insights from the Webinar with CEO Nigel Lange
On June 6, 2024, Sharewise hosted an enlightening webinar featuring Nigel Lange, the Managing Director and CEO of OncoSil Medical Ltd. This session provided investors and stakeholders a comprehensive update on OncoSil Medical’s strategic advancements, ongoing clinical trials, and future aspirations. Here’s a detailed look at the key takeaways from the webinar. How Does the […]
June 21, 2024
OncoSil Medical’s (ASX: OSL) Successful Capital Raise to Support Clinical Trials
Key Highlights What’s New? OncoSil Medical Ltd has successfully raised $5.3 million through a non-renounceable entitlement offer and this money is being used to finance expansions and commercialization as well as further clinical trials across the world. Why it Matters? Commercialisation of OncoSil Product The OncoSil device is increasingly used in hospitals, with the device […]
June 20, 2024
OncoSil Medical (ASX: OSL) Advances Pancreatic Cancer Treatment with PANCOSIL Trial
In the relentless battle against pancreatic cancer, innovative approaches are pivotal. OncoSil Medical Limited (ASX) is at the forefront of this fight with their pioneering device, OncoSilâ„¢. The company is thrilled to announce the treatment of the fifth patient in the ongoing PANCOSIL Investigator Initiated Clinical Trial. This milestone not only underscores the progress of […]
June 19, 2024
OncoSil Medical (ASX:OSL) Results of Annual General Meeting
On 29 November 2023, OncoSil Medical Ltd, a medical device company focusing on localised treatments for patients with locally advanced pancreatic cancer (LAPC), held its Annual General Meeting (AGM) in Melbourne, Australia. AGM Presentation Highlights OncoSil Medical has made notable progress over the past year, marked by significant regulatory achievements and early commercial success. The […]
June 10, 2024
OncoSil Medical (ASX: $OSL) raises $5.3 million under entitlement offer
Overview of OncoSil Medical’s recent announcement OncoSil Medical Limited (ASX: $OSL) has successfully raised $5.3 million under its non-renounceable entitlement offer, allowing eligible shareholders to subscribe for 1 new share for every 2 shares held at the record date of 28 March 2024. The issue price for the new share was $0.005, and additional long-dated […]
June 10, 2024
OncoSil Medical (ASX: OSL) Signs Exclusive 3-Year Distribution Agreement for Saudi Arabia
Key Findings What is OncoSil Medical? OncoSil Medical Limited (ASX: OSL) is a company that has developed a cancer treatment device called the OncoSilâ„¢ brachytherapy device. This device is a critical component of a revolutionary brachytherapy treatment for locally advanced unresectable pancreatic cancer. Pancreatic cancer is the 12th most common cancer in men and the […]
June 10, 2024
Pancreatic Cancer Battle Heats Up with The Biotech Sector’s Advanced Treatments
The fight against pancreatic cancer, a notoriously aggressive disease with historically low survival rates, is entering a new era of hope. Advancements in the biotech sector are leading the charge, offering breakthroughs in both early detection and innovative treatment options. This article explores these advancements, highlighting the potential of a groundbreaking blood test and the […]
June 10, 2024
OncoSil Medical (ASX: OSL) Gears Up: A Month of Strategic Moves in May 2024
In the dynamic field of medical technology, OncoSil Medical Ltd. (ASX: OSL) has made significant strides in May 2024, marking a month of crucial developments and strategic advancements. Known for its pioneering work in cancer treatment technologies, OncoSil has continued to innovate and expand its reach, bolstered by recent financial and strategic manoeuvres. Here, we […]
June 10, 2024
OncoSil Medical: A Prime Investment Opportunity in the Booming ASX Healthcare Sector
As we step into 2024, the ASX healthcare sector presents a compelling case for investors seeking growth and stability. The sector is buoyed by several positive trends, making it an attractive proposition. Among the standout companies within this sector is OncoSil Medical, whose innovative advancements in pancreatic cancer treatment are generating significant interest and optimism. […]
June 10, 2024
Targeted Radiation Therapy: OncoSilâ„¢ for Pancreatic Cancer
OncoSilâ„¢ is a single-use brachytherapy device designed for patients with locally advanced unresectable pancreatic cancer (LAPC). It delivers a targeted dose of beta radiation directly into cancerous tissue, working alongside traditional chemotherapy. This approach aims to reduce tumour size, potentially making patients eligible for surgical removal. Brachytherapy, also known as internal radiation therapy, distinguishes itself […]
June 10, 2024
OncoSil: Ushering in a New Era of Hope – The OncoSil™ Device Enters Early-Stage Commercialization
For decades, pancreatic cancer has cast a long shadow, with its aggressive nature and dismal prognosis leaving patients with limited hope. But with the early-stage commercialization of OncoSil, a ground-breaking technology from OncoSil Medical Ltd. (ASX: $OSL) that offers a focused and potentially game-changing approach to treating this debilitating disease, a new era is beginning. […]
June 10, 2024
OncoSil Medical (ASX: $OSL) expands European footprint with first Austria-based treatments
OncoSil Medical’s Milestone in UK Clinical Study OncoSil Medical Limited (ASX: $OSL) has achieved a significant milestone as the first patient in the UK was treated with the OncoSil device for the TRIPP-FXX clinical study, conducted at The Hammersmith Hospital in London. Executive Commentary on Milestone Achievement The first patient treatment using the OncoSil device […]
June 8, 2024
OncoSil (ASX: OSL) Eyes Global Expansion in Capital Raise
Pancreatic cancer is a difficult disease to treat. In 2020 alone, a total of 495,773 new cases emerged with 466,003 deaths of 246840 males and 219163 females. Companies like OncoSil are trying to change this. Oncosil Medical Limited (ASX: OSL) is an Australian-listed medical device company that focuses on localised treatments for patients with pancreatic […]
June 8, 2024
OncoSil Medical Strengthens Fight Against Pancreatic Cancer with Successful $5.3 Million Capital Raise
OncoSil Medical Ltd. (ASX: OSL), a leading biotechnology company focused on developing treatments for pancreatic cancer, has concluded a successful capital raising initiative. The company secured $5.3 million through its recent non-renounceable entitlement offer (Entitlement Offer), which closed in April 2024. This strong showing by existing shareholders indicates significant confidence in the company’s mission and […]
June 7, 2024
OncoSil Medical (ASX: OSL) Signs Exclusive 3-Year Distribution Agreement for Saudi Arabia
Key Findings What is OncoSil Medical? OncoSil Medical Limited (ASX: OSL) is a company that has developed a cancer treatment device called the OncoSilâ„¢ brachytherapy device. This device is a critical component of a revolutionary brachytherapy treatment for locally advanced unresectable pancreatic cancer. Pancreatic cancer is the 12th most common cancer in men and the […]
June 6, 2024
OncoSil (ASX: OSL): A Biotech Stock with 30-Bagger Potential
Biotech stocks are known to have long lead times, underperforming in the early years and then gaining once they have established themselves in the market. Over the years, these stocks, considered risky at first, have tended to perform well after their products are adopted and used in the marketplace. Although stocks like Oncosil (ASX: OSL) […]
May 16, 2024
OncoSil Medical (ASX: OSL) Price to See Long Term Boost
OncoSil Medical Ltd. (ASX: OSL) is a global medical device company that focuses on interventional oncology, with the mission to improve the outcomes for people living with cancer by utilising selective and targeted intratumoral placement of Phosphorous 32 (32P) Microparticles. The Oncosil device focuses on using localised radiation therapy for the treatment of pancreatic cancer. […]
May 16, 2024
Analysts Predict Oncosil Medical (ASX: OSL) Will Breakeven Soon
OncoSil (ASX: OSL) is arguably one of the most innovative treatments available for pancreatic cancer patients and the company could be approaching a most significant turning point. In this article, we take stock of Oncosil’s (ASX: OSL) share price performance, expansion efforts, and the prospects for the coming years. Like most biotech stocks, the first […]
May 15, 2024
OncoSil Secures $5.3 Million via Entitlement Offer, Fueling Growth of Localised Pancreatic Cancer Treatment
OncoSil Medical Limited (ASX: $OSL) has successfully concluded its non-renounceable entitlement offer, raising $5.3 million in crucial capital to propel the development and commercialisation of its innovative OncoSilâ„¢ device for localised pancreatic cancer treatment. This article dives into the details of the offer, explores its significance for OncoSil’s future, and analyses the broader implications for […]
May 15, 2024
OncoSil Medical Unveils Groundbreaking Results: Enhancing Pancreatic Tumour Vascularity
Pancreatic cancer remains a formidable foe, stubbornly clinging to its reputation as one of the most challenging malignancies to combat. Dismal survival rates have painted a bleak picture for patients grappling with this aggressive disease. However, a recent study by OncoSil Medical Limited (ASX: OSL) has emerged as a beacon of hope, unveiling groundbreaking results […]
May 15, 2024
OncoSil Medical (ASX: $OSL) Makes Strong Progress in Q3 FY24: European Expansion, New Distribution Deal, and Capital Raise
OncoSil Medical Ltd. (ASX: $OSL), a medical device company focused on innovative localised treatments for patients with pancreatic cancer, recently revealed its Quarterly Activities & Cash Flow Report for the quarter ended March 31, 2024 (Q3 FY24). The report paints a promising picture for investors, outlining strategic advancements and financial strength. With a clear focus […]
May 15, 2024
Top Three Cancer Treatment Devices
According to the World Health Organisation (WHO), cancer is the second leading cause of death globally and several medical devices are emerging in the field of oncology with promising results in detecting and treating the disease. While many cancers can be kept away with a healthy lifestyle, only one in two people will develop the […]
April 26, 2024
OncoSil Medical (ASX: OSL) Scores Another Win: Two More Patients Enrolled in PANCOSIL Trial
OncoSil Medical Ltd. (ASX: OSL) (“OncoSil”), a leader in localised treatment solutions for locally advanced pancreatic cancer (LAPC), has announced exciting progress in the PANCOSIL Investigator Initiated Clinical Trial. Following the first successful patient treatment in November 2023, two more patients have been enrolled and treated with the innovative OncoSilâ„¢ device in April 2024. Expanding […]
April 26, 2024
Three Types of Treatments for Pancreatic Cancer
Between 2024 and 2036, the pancreatic cancer market is predicted to increase by 18%. By the end of 2036, the market is predicted to produce USD 36 billion in sales, up from around USD 6 billion in 2023. The market is growing as pancreatic cancer becomes increasingly widespread worldwide. The American Cancer Society predicts that […]
April 26, 2024
OncoSil (ASX: OSL) Treatment Expanding at a Rapid Pace
Pancreatic cancer is notoriously difficult to treat and the total number of cases was estimated at 495,773 in 2020 alone, with over 246840 males and 219163 females impacted by this form of cancer. While traditional chemotherapy has been used for several decades, it causes debilitating pains and increases recovery times. Oncosil is changing this, but […]
April 24, 2024
OncoSil Medical (ASX: OSL) Treatment Expands in Northern Europe
Three patients have been treated with the OncoSilâ„¢ device in the Netherlands at the PANCOSIL Investigator-Initiated Clinical Trial. The trials are being conducted at the AMC Medical Centre in Amsterdam in collaboration with OncoSil Medical. This Trial tests the safety and feasibility of percutaneous radionuclide therapy (RNT), a form of treatment that can be performed […]
April 24, 2024
Actinogen Medical (ASX: ACW) Xanamem for Depression
Depression is a widely experienced mental disorder, with around 5% of adults suffering from major depressive disorder (MDD), which often leads to unclear thinking. Recent clinical trials suggest that a new oral medication, taken daily, could offer significant improvements. The drug, Xanamem®, shows potential to help patients who find that antidepressant medications alone do not […]
April 18, 2024
Actinogen Medical’s XanaMIA Phase 2b Alzheimer’s Disease Trial
In a landmark moment for medical science, Actinogen Medical (ASX: ACW) has announced the initiation of its XanaMIA phase 2b clinical trial, marking a significant step forward in the pursuit of a breakthrough treatment for Alzheimer’s disease (AD). The first patient was randomised and treated on Friday, April 12th, heralding the commencement of a trial […]
April 17, 2024
Breaking Barriers: OncoSil Medical Secures Reimbursement Approval in the UK
In a significant stride forward, OncoSil Medical Ltd. (ASX: OSL) announces a pivotal achievement in its mission to revolutionize pancreatic cancer treatment. One of the largest private insurance companies in the UK has agreed to provide reimbursement for the OncoSilTM device at Imperial College Healthcare NHS Trust, a renowned institution based in London, England. Imperial […]
April 12, 2024
Major Insurer Approves OncoSil in UK
After a year of control and clinical trials, expansion, and commercialisation in over 38 countries and a capital raise designed to reinforce OncoSil’s market presence, a major insurer in the UK has given its stamp of approval for the ground-breaking cancer treatment. At Imperial College Healthcare NHS Trust, one of the largest private insurance companies […]
April 12, 2024
OncoSil Medical: Biotech with Proven Leadership
Oncosil is a single-use internal radiation device that delivers a dose of predetermined beta radiation directly into pancreatic cancerous tissue. The radiation only goes to the cancer cells and doesn’t affect the surrounding tissue, such as other vital organs located nearby. The OncoSil device is branded as one of the most innovative ways of treating […]
April 12, 2024
OncoSil (ASX: OSL) Device Expands to AustriaÂ
Two patients have been treated for Pancreatic cancer using the OncoSil device Oncosil plans to expand to other European Countries such as the UK, Portugal, and Germany Past expansions have preceded revenue growth. Revenues grew 37% between 2022 and 2023.  The first patients residing in Austria have received treatments involving the OncoSil device. Both […]
April 5, 2024
OncoSil (ASX: OSL) Eyes Global Expansion in Capital Raise
Pancreatic cancer is a difficult disease to treat. In 2020 alone, a total of 495,773 new cases emerged with 466,003 deaths comprised of 246840 males and 219163 females. Companies like OncoSil are trying to change this. Oncosil Medical Limited (ASX: OSL) is an Australian-listed medical device company that focuses on localised treatments for patients with […]
April 5, 2024
OncoSil: Ushering in a New Era of Hope – The OncoSilâ„¢ Device Enters Early-Stage Commercialization
For decades, pancreatic cancer has cast a long shadow, with its aggressive nature and dismal prognosis leaving patients with limited hope. But with the early-stage commercialization of OncoSil, a ground-breaking technology from OncoSil Medical Ltd. (ASX: $OSL) that offers a focused and potentially game-changing approach to treating this debilitating disease, a new era is beginning. […]
April 1, 2024
OncoSil Medical Sets Sights on Global Expansion with Strategic Investments
Imagine a future where innovative cancer treatments reach patients across the globe, offering hope and healing. This is the ambitious vision that OncoSil Medical (ASX: $OSL), a leading Australian healthcare company, is actively pursuing. The company recently unveiled its investor presentation, outlining a strategic roadmap that prioritises global expansion. This focus on international markets is […]
March 27, 2024
Oncosil Set to Raise $7.1 Million to Expand Commercial Activities
Oncosil Medical Limited (ASX: OSL) is an Australian-listed medical device company that is focused on localised treatments for patients with pancreatic cancer and liver cancer. Its medical device is equipped with targeted radioactive isotopes (Phosphorous-32) and is implanted directly into the patient’s pancreatic tumours in a treatment known as brachytherapy, to deliver concentrated and localised […]
March 27, 2024
OncoSil Medical Ltd: Fueling Innovation in Cancer Treatment with a $7.1 Million Capital Raise
OncoSil Ltd. (ASX: OSL), a leading Australian biotechnology company, is poised to revolutionise cancer treatment with its innovative OncoSil platform. To accelerate this mission and expand its reach, OncoSil is undertaking a capital raise of over $7 million AUD. This strategic move will unlock the potential of the OncoSil device, generating significant revenue streams from […]
March 22, 2024
OncoSil Accessible At 11 Prestigious Hospitals Across Spain
OncoSil Medical Limited (ASX: $OSL) Pancreatic cancer treatment device company, has announced its availability at eleven prestigious hospitals across Spain. This expansion signifies a significant step towards increased accessibility of this innovative treatment for cancer patients in the region. In the recently published half-yearly report, they said that in Spain a total of 20 patients […]
March 18, 2024
Are HealthCare CEOs Overpaid in the Australian Exchange?Â
As earnings season approaches, CEO pay in the health care sector is coming under scrutiny. After all, inflation is high and consumers have less cash in their pockets. However, it is important to judge CEO pay based on what their peers make in the industry. The health care sector in Australia is innovative and in […]
March 14, 2024
Nigel Lange leading OncoSil after selling Sirtex for over a billion dollars
In 2018, Varian Medical Systems announced it had signed an agreement to acquire all the outstanding shares of Sirtex Medical Limited (ASX: $SRX) (“Sirtex”), an Australia-based global life sciences company focused on interventional oncology therapies. Sirtex was acquired by the company for a huge USD 1.23 billion. The CEO of Sirtex was Nigel Linge and […]
March 14, 2024
Precise Pancreatic Cancer Treatments That Disrupt MarketsÂ
Key Takeaways Pancreatic cancer is on the rise across the rich world Most treatments involve a mix of surgery and radiation, with long recovery times Oncosil targets cancerous cells and reduces the negative impact on surrounding tissues or organs  Pancreatic cancer is on the rise and there are four major ways of treating it […]
March 12, 2024
Top 5 Health Care Stocks From Reddit
Finding the right stock to invest in requires time, industry-relevant knowledge, and days if not months of research. However, it is sometimes good to see what real-life individual investors are looking at and/or investing in to inform your trades. After careful evaluation, this article lists the top five stocks to watch in 2024 based on […]
March 12, 2024
Potential ASX Multi-Bagger Biotech Stocks
The biotechnology sector has always been a hotbed of innovation and investment potential, we are living in the 21st century and thinking of habituating on Mars the same way we are progressing in our medical science too. As we navigate through an era of groundbreaking advancements in medical science, some of the ASX-listed biotech stocks […]
March 12, 2024
OncoSil half-yearly report: Key highlights
OncoSil Medical Limited (ASX: $OSL) Pancreatic cancer treatment device company reported its half-yearly performance recently, and there are many significant milestones achieved by the company before diving into the report further, let’s see what the CEO & Managing Director Nigel Lange said: “The December 2023 half saw further significant progress made in our efforts to […]
March 12, 2024
Dr. Gabriel Liberatore: Bringing Experience and Success to OncoSil
OncoSil Medical Ltd. (ASX: $OSL), a company developing a novel treatment for pancreatic cancer, announced on 14 July 2023, Dr Gabriel Liberatore to the Board as a Non-Executive Director to its board of directors. As OncoSil advances many recent globalisation achievements during this time, this strategic move offers a wealth of experience and a demonstrated […]
March 4, 2024
OncoSil Reports Progress in Clinical Trials and Commercialisation of OncoSil Device
OncoSil Medical Ltd. (ASX: $OSL), a leading pancreatic cancer treatment device company, has recently unveiled significant advancements in its quest to revolutionise pancreatic cancer treatment. As detailed in the ASX announcement dated February 28, 2024, covering the half-year period ending December 31, 2023, OncoSil has achieved remarkable milestones in both its clinical trial programmes and […]
March 4, 2024
Oncosil (ASX: $OSL) – Technical Analysis Points to a Promising Path Forward
The healthcare sector is brimming with exciting opportunities for investors seeking long-term growth. Among these, Oncosil (ASX: $OSL) is attracting increasing attention due to a compelling confluence of technical indicators and promising recent achievements. This analysis delves into OncoSil’s technical landscape, highlighting positive signals, and explores the company’s recent milestones that could pave the way […]
March 4, 2024
Revealing a Hidden Treasure for Value Investors
The finance sector is full of hidden gems that are just waiting for someone with a keen sense of value to discover them. For value investors, the current market climate presents exciting possibilities, and Oncosil Medical (ASX: $OSL) stands out as a particularly compelling opportunity. This article delves into the reasons why $OSL, with its […]
March 4, 2024
Biotech Stock VS Crypto Market
In the realm of investments, there are abundant opportunities in traditional sectors as well as emerging technologies. Today, we’ll examine OncoSil Medical ($OSL) and cryptocurrencies to understand their market potential and growth paths. Finance offers a variety of assets, each with distinct characteristics and growth prospects. While cryptocurrencies remain in the spotlight, established markets such […]
March 1, 2024
OncoSil Medical: Anticipating Accelerated Growth in 2024 Amid Expected Rate Cuts
Interest Rates Pivoting will Fuel this Biotech Stock As global economies adjust to the challenges of inflation and growth, central banks’ monetary policies, particularly adjustments in interest rates, play a crucial role in defining the investment environment. In Australia, the anticipation of rate cuts has ignited optimism across various sectors, especially within the biotech and […]
February 27, 2024
Actinogen’s Rise Under CEO Dr. Steven Gourlay
Actinogen Medical (ASX: $ACW) has experienced a notable ascent in the biotech sector, with its shares climbing over 115% this year. At the helm of these advancements is CEO Dr. Steven Gourlay, whose leadership is directly correlated with the company’s recent success. Today, let’s dive into the fascinating world of Dr. Steven Gourlay, the mastermind […]
February 21, 2024
OncoSil: The Next Sirtex?
OncoSil Medical Ltd (ASX: OSL) aims to make a difference in cancer treatment by selectively targeting tumors while sparing healthy tissue. Their flagship product, OncoSilTM, delivers targeted radiation for pancreatic cancer and has major growth potential by following the blueprint of Sirtex Medical’s success. OncoSil specializes in an innovative brachytherapy device, OncoSilTM, that is implanted […]
February 20, 2024
Pancreatic Cancer Breakthrough Treatment “OncoSilâ„¢” Acquires European Certification
The British Standards Institute (BSI) has granted the OncoSil System the prestigious European CE marking. This certification validates the OncoSil device and its clinical performance in treating locally advanced pancreatic cancer. Additionally, OncoSil has been designated as a breakthrough therapy, acknowledging its potential to address unmet medical needs. CE Marking Certification CE stands for Conformité […]
February 9, 2024
The Benefit of Using OncoSil (ASX: $OSL)
Pancreatic cancer is the fourth leading cause of cancer death in both men and women. About 15% of all pancreatic cancer tumours are resectable. Stage IV pancreatic cancer has a five-year survival rate of 1 percent. OncoSil Medical is changing the way we treat pancreatic cancer. Â In Europe, pancreatic cancer is currently the seventh […]
February 8, 2024
This Cancer Stock Will Go Up 3 281%
This cancer stock doubles the survival rate with little to no downside compared to other cancer treatments. What’s more? This gem has just been green-lit for insurance reimbursement approval for 84 German hospitals, making it a financial goldmine.  Mr Nigel Lange, former CEO of the bombed-out biotech, Sirtex Medical, was recognized as a global […]
February 8, 2024
OncoSil Medical (ASX: $OSL) at the ASCO GI Cancers Symposium
From January 18-20, 2024, OncoSil Medical Ltd. (ASX: $OSL) participated in the ASCO Gastrointestinal Cancer Symposium in San Francisco, CA. This event highlighted the latest trends and collaborations in oncology, with a special focus on gastrointestinal cancers. Key Insights: OncoSil’s engagement at the ASCO-GI Symposium. Partnership discussions with the Cholangiocarcinoma Foundation. The potential impact of […]
February 5, 2024
Actinogen Medical (ASX: $ACW) or Alto Neuroscience?
In recent years, the world has started to pay more attention to mental health, recognising how important it is. Mental health issues, including problems with alcohol or drug use, are becoming more common, now affecting one in eight people worldwide. Conditions like depression and anxiety are not only widespread but also costly, taking a toll […]
February 5, 2024
Actinogen Medical: Advancing the Fight Against Alzheimer’s and Beyond
Actinogen Medical (ASX: ACW) is a clinical-stage biopharmaceutical company pioneering a novel approach to treating neurodegenerative diseases and neuropsychiatric conditions. Their lead candidate, Xanamem, is a first-in-class oral medication that targets brain cortisol, offering a promising new avenue for tackling Alzheimer’s disease (AD), major depressive disorder (MDD), and other debilitating neurological disorders. Following the Science: […]
January 30, 2024
Actinogen Medical’s 2024 Roadmap: Converging Strategies for Growth
Actinogen Medical has set a robust agenda for 2024, strategically aligning its priorities to steer the company towards growth and innovation. This comprehensive plan encompasses forward-thinking strategies, accelerated clinical development, and a focus on creating value through strategic partnerships. Forward Planning for Future Triumphs In the realm of forward planning, Actinogen Medical is gearing up […]
January 30, 2024
ACW Rises 20% : Discovering the Factors Driving to the Growth of Actinogen Medical
Actinogen Medical Ltd (ACW) has been attracting substantial attention in the volatile and unpredictable realm of financial markets. The company’s stock has had a significant increase of 20%, indicating a possible change in momentum following a period of relative steadiness. This spike is remarkable since it comes after multiple efforts by ACW in the last […]
January 30, 2024
OncoSil Blazes Trails in Cancer Treatment: Advancing Prognosis and Expanding Reach
OncoSil Medical (ASX: OSL) is making waves in the fight against cancer, with recent milestones showcasing its commitment to cutting-edge therapies and global expansion. This Australian medical device company is dedicated to transforming lives through localized treatments for challenging cancers, particularly locally advanced pancreatic cancer (LAPC). Expanding Horizons: Global Recognition and Partnerships Just last week, […]
January 30, 2024
Revolutionizing Pancreatic Cancer Care: OncoSil’s Breakthrough Treatment Milestone
OncoSil Medical Ltd (ASX: OSL) has achieved a significant milestone by successfully commencing its first OncoSil therapy at Dr. Peset University Hospital in Valencia. This milestone signifies a notable advancement in the treatment of pancreatic cancer, showcasing the pioneering progress achieved by OncoSil in the realm of cancer treatment. OncoSil’s Revolutionary Treatment OncoSil’s proprietary treatment, […]
January 30, 2024
Oncosil Medical: Spearheading Innovation and Collaboration at ASCO Gastrointestinal Cancers Symposium
OncoSil Medical Ltd (ASX: OSL) presented significant advancements and collaborations during the ASCO Gastrointestinal Cancers Symposium held in San Francisco, CA from January 18-20, 2024. This conference is esteemed among oncology professionals and provides a forum for discussing cutting-edge research and progress in the field of gastrointestinal cancer, including its prevention, diagnosis, and multimodal treatment. […]
January 30, 2024
RNA Interference Breakthrough: Unraveling the Role in Alzheimer’s Disease
A novel study reveals the pivotal role of RNA interference in Alzheimer’s disease, shedding light on a potential breakthrough in treatment strategies. Researchers at Northwestern University have uncovered a delicate balance between toxic and protective short RNAs (sRNAs) in aging and Alzheimer’s-affected brains, offering a novel perspective on the mechanisms leading to brain cell death […]
January 26, 2024
Unveiling Alzheimer’s Diversity: Researchers Identify 5 Sub Variants of the Disease
In a groundbreaking revelation, researchers from Amsterdam University Medical Centers and Maastricht University have identified five distinct biological variants directly linked to Alzheimer’s disease. This discovery, featured in the journal Nature Aging, carries immense implications for the future landscape of Alzheimer’s treatment. The Complexity of Alzheimer’s With approximately 32 million individuals worldwide battling Alzheimer’s, this […]
January 26, 2024
Xanamem: Illuminating Hope in Neurological Therapeutics
In the intricate tapestry of neurological research, Xanamem emerges as a beacon of hope, offering a transformative once-a-day treatment with a unique, non-amyloid/non-tau mechanism. Developed by Actinogen Medical, Xanamem is a brain-penetrant 11β-HSD1 small molecule enzyme inhibitor designed to reduce brain cortisol, presenting a novel approach to addressing cognitive challenges. The potential of Xanamem extends […]
January 26, 2024
Tackling the Alzheimer’s Challenge: Actinogen Medical’s Xanamem® Promises Hope
Alzheimer’s disease, a progressive neurological condition predominantly affecting older adults, continues to cast a shadow over the lives of millions worldwide. Characterized by a gradual decline in cognitive abilities, this debilitating condition robs individuals of their memory, reasoning, and communication skills. With over 55 million people grappling with dementia globally, Actinogen Medical (ASX: ACW) emerges […]
January 26, 2024
Unlocking the Future of Neurological Therapies: Actinogen Medical and the Xanamem® Breakthrough
In the world of biotechnology, Actinogen Medical (ASX: ACW) is making waves with its innovative strides in neurological and neuropsychiatric research. At the forefront of their pioneering work is Xanamem®, a game-changing therapy targeting cognitive dysfunction associated with imbalanced brain cortisol. Recent developments showcase the company’s exciting progress and hint at a promising future, making […]
January 26, 2024
How Obesity Paves the Way for a 20% Increased Risk of Pancreatic Cancer
Pancreatic cancer is a formidable opponent in the world of oncology, presenting a complex challenge when it comes to timely diagnosis and effective treatment. Gaining a comprehensive understanding of the various risk factors linked to this dangerous threat is essential, and recent research has provided valuable insights into a major contributing factor: obesity. Understanding Obesity […]
January 26, 2024
Unmasking the Silent Threat: Navigating the Challenges of Early Diagnosis and Treatment in Pancreatic Cancer
Pancreatic cancer, often asymptomatic in its early stages, poses a significant challenge for timely diagnosis and treatment. By the time symptoms manifest, the disease has typically reached advanced stages, limiting the effectiveness of traditional treatments such as surgery, chemotherapy, and radiation. In this context, OncoSil emerges as a beacon of hope, offering a groundbreaking approach […]
January 26, 2024
Breaking Barriers: The five-year survival rate for pancreatic cancer
In a groundbreaking revelation, the American Cancer Society’s Cancer Facts & Figures 2024 Report has announced a consecutive one percentage point increase in the five-year survival rate for pancreatic cancer, now standing at 12%. This steady progress signifies a glimmer of hope for individuals grappling with this challenging disease, offering the promise of extended life […]
January 26, 2024
Revolutionizing Pancreatic Cancer Treatment: The Role of OncoSilâ„¢ in the Pursuit of Hope
Pancreatic cancer, known for its silent but formidable presence, ranks among the deadliest forms of cancer globally. Despite being the twelfth most diagnosed cancer, it holds the seventh highest fatality rate, with a mere 5 to 10 percent 5-year survival rate. These grim statistics underscore the urgent need for innovative treatments, prompting a closer examination […]
January 26, 2024
OncoSilâ„¢ Paves the Way for Pancreatic Cancer Breakthrough with PANCOSIL Clinical Trial
In a groundbreaking development, OncoSil Medical Ltd (ASX: OSL), a leading medical device company specializing in localized treatments for locally advanced pancreatic cancer (LAPC), has achieved a crucial milestone with the approval of the PANCOSIL Investigator Initiated Clinical Trial by the ethics committee. This significant step underscores OncoSil’s commitment to innovation and patient-centric care, positioning […]
January 26, 2024
OncoSil Medical Marks Milestone with Successful Pancreatic Cancer Treatment
OncoSil Medical (ASX: OSL) has marked a critical milestone by successfully treating pancreatic cancer in Europe with its flagship OncoSil device. The surgery, carried out at Madrid’s Hospital Universitario de Fuenlabrada, is a significant step forward in localized cancer therapy. As OncoSil advances in the area, investors and healthcare enthusiasts see encouraging developments that position […]
January 26, 2024
OncoSil Medical Marks Milestone with Successful Pancreatic Cancer Treatment
OncoSil Medical (ASX: OSL) has marked a critical milestone by successfully treating pancreatic cancer in Europe with its flagship OncoSil device. The surgery, carried out at Madrid’s Hospital Universitario de Fuenlabrada, is a significant step forward in localized cancer therapy. As OncoSil advances in the area, investors and healthcare enthusiasts see encouraging developments that position […]
January 22, 2024
OncoSil Medical Ltd. Advances Pancreatic Cancer Treatment with Percutaneous Clinical Trial
An important milestone has been reached when the ethics committee approved the ground-breaking PANCOSIL clinical study for OncoSil Medical Ltd (ASX: OSL), a leading medical device firm that specializes in localized treatments for locally advanced pancreatic cancer (LAPC). Under the direction of renowned professor Marc Besselink of Amsterdam UMC, this Investigator Initiated Clinical Trial represents […]
January 22, 2024
Revolutionizing Pancreatic Cancer Treatment: The Promise of Contact X-Ray Brachytherapy
Pancreatic cancer treatment has traditionally involved rigorous protocols, often incorporating radiation therapy, chemotherapy, and invasive surgical procedures. For many patients, particularly those over 65, finding safer and more effective alternatives that prioritize organ preservation is imperative to mitigate the risk of morbidity and mortality. The Watch and Wait (W&W) treatment emerges as a novel non-surgical […]
January 22, 2024
Revolutionizing Cancer Treatment: OncoSilâ„¢ Brachytherapy System
In the ever-evolving landscape of cancer treatment, OncoSilâ„¢ emerges as a beacon of hope for patients with locally advanced unresectable pancreatic cancer (LAPC). Developed as a single-use brachytherapy device, OncoSilâ„¢ delivers a precisely determined dose of beta radiation directly into cancerous tissue, complementing traditional chemotherapy. This revolutionary approach, rooted in brachytherapy, offers a targeted solution […]
January 22, 2024
OncoSil Medical (ASX:OSL) Results of Annual General Meeting
On 29 November 2023, OncoSil Medical Ltd, a medical device company focusing on localised treatments for patients with locally advanced pancreatic cancer (LAPC), held its Annual General Meeting (AGM) in Melbourne, Australia. AGM Presentation Highlights Corporate Overview:Â OncoSil Medical, listed on ASX under the ticker $OSL since 15 August 2005, holds a market capitalisation of $15.8 […]
December 12, 2023
Valuation Metrics: Is OncoSil Medical Undervalued?
Valuation Metrics: Is OncoSil Medical Undervalued? Introduction Assessing the valuation of a company is a critical aspect of investment analysis. In this article, we will explore the valuation metrics for OncoSil Medical Ltd (OSL.AX) to determine whether the company is undervalued, overvalued, or fairly priced in the market. Price-to-Sales (P/S) Ratio The Price-to-Sales (P/S) ratio […]
November 24, 2023
ACW Stock Analysis: Actinogen’s Journey to Transform Neurology Care
ACW Stock Analysis: Actinogen’s Journey to Transform Neurology Care In the complex and ever-evolving landscape of healthcare, the field of neurology care stands as a beacon of hope for individuals grappling with neurological diseases. At the forefront of this transformative journey is Actinogen Medical, a company that envisions a brighter future for patients and their […]
November 23, 2023
Investing in Excellence: Actinogen’s Pursuit of Quality Neurotherapeutics
Investing in Excellence: Actinogen’s Pursuit of Quality Neurotherapeutics In the ever-evolving world of healthcare, the pursuit of excellence is a quest that shapes the future of medicine. At the forefront of this endeavor is Actinogen Medical, a company that believes in the transformative power of quality neurotherapeutics. This article explores the significance of quality in […]
November 23, 2023
Navigating the Medical Technology Sector: OncoSil’s Business Operations
Navigating the Medical Technology Sector: OncoSil’s Business Operations Operating in the medical technology sector, OncoSil Medical Ltd (OSL.AX) is on a mission to redefine cancer treatment. In this article, we will explore the business operations of OncoSil, focusing on the company’s strategic approach, key milestones, industry presence, and global expansion efforts. Strategic Focus: The OncoSil™ […]
November 23, 2023
Unlocking the Future of Neurotherapeutics Actinogen Medical and Xanamem
Navigating the Medical Technology Sector: OncoSil’s Business Operations Operating in the medical technology sector, OncoSil Medical Ltd (OSL.AX) is on a mission to redefine cancer treatment. In this article, we will explore the business operations of OncoSil, focusing on the company’s strategic approach, key milestones, industry presence, and global expansion efforts. Strategic Focus: The OncoSilâ„¢ […]
November 6, 2023
Breaking Ground in Cognitive Health: Actinogen Medical’s Latest Progress with Xanamem
Breaking Ground in Cognitive Health: Actinogen Medical’s Latest Progress with Xanamem In the pursuit of innovative solutions for cognitive and neuropsychiatric disorders, Actinogen Medical, an Australian biotechnology firm, has been steadily advancing a groundbreaking treatment known as Xanamem. As of August 2023, Actinogen Medical has made significant strides in the development of Xanamem, with promising […]
November 6, 2023
ASX News, First
& Fast.
ASX News, First And Fast.
All rights reserved
